This evaluation study uses a mixed-methods convergent design using both qualitative and quantitative data to ensure a more complete understanding of the effectiveness of the program.
Phases of the study include:
1. A pre-program survey to provide a baseline assessment of attitudes towards dementia; preparedness for the caregiver; knowledge of dementia; and caregiver self-efficacy
2. Access to the self-guided program for 30 days
3. A post-program survey assessing the impact of the training intervention on attitudes towards dementia; preparedness for the caregiver; knowledge of dementia; and caregiver self-efficacy
4. 3 focus groups with 4-10 participants each to learn more about the experience of trying the IncludeMe™ - A starting point for Dementia caregivers program.
After descriptive and thematic analysis, several final reports will be made available highlighting key findings.
You are eligible to participate if you are a caregiver to a person living with dementia or exhibiting signs of dementia, live in Ontario and aged 18 or older.
Ability to speak English
The Nighttime Insomnia Treatment and Education for Canadians with Alzheimer’s Disease (NITE-CAD) team is lifestyle intervention program to support care partners in helping improve sleep in people living with dementia. This program is based on an American program that has been modified to meet the needs of Canadians. The NITE-CAD program takes place over 6-weeks and consists of 1) education and goal setting, 2) self-directed physical activity, and 3) bright light exposure. This study is to help ensure the NITE-CAD program is feasible for future offerings.
• Care partner to someone living with dementia with sleep difficulties
• Are living with dementia experiencing sleep difficulties, with a live-in care partner who is interested in participating
• Able to speak and understand English
• Have access to the internet and a computer with a camera and microphone
• Able to participate in an exercise program
• Sufficient cognitive function to follow two-step commands.
Alert systems such as United States’ Silver Alert and Scotland’s Purple Alert support first responders in locating missing persons with dementia. In Canada, provinces are responsible for Silver Alerts. To date, Alberta and Manitoba amended Missing Persons Acts, but have no Silver Alerts. British Columbia has a citizen-led Silver Alert, yet no provincial legislation. This study examines how policies and programs for alert systems are developed and implemented in Canada, Scotland, and the United States. Findings will inform policies and implementation of alert systems to optimize the safety and well-being of people living with dementia at risk of going missing.
have experience or interest in using BC Silver Alert to locate missing persons with dementia and are a/an:
• Person living with dementia
• Care partner
• Alzheimer Society staff
• First responder
• Service provider
• Technology developer
• Policy maker
Caregivers of people living with dementia experience significant stress which can negatively affect their mental health. The overall aim of the current study is to evaluate a newly developed app that focuses on providing stress-management strategies for family caregivers of people living with dementia. Findings from the study of an app that aims to address the stressors associated with caregiving has the potential to improve the quality of life of caregivers of people living with dementia.
- Providing informal and unpaid care (e.g., spouses, children) for people living with dementia
- Providing primary care (i.e., most of the care or equally shares the care with another individual such as a mother or sibling) for the person living with dementia
- Own a smartphone (e.g., iPhone, Android)
- Not currently using a mobile app created for caregivers
- Ability to speak English
Surveying opinions on how to improve diversity in dementia research.
You are eligible to participate if you are:
1) Involved in dementia research or services
AND / OR
2) from an underserved group* in dementia research.
3)Aged 19 +
3)Able to complete the web-based survey in one of the following languages: English, French, Chinese (simplified), Punjabi, Inuktitut.
*Underserved groups in dementia research include: Racial/ethnic minorities (i.e., South Asian, Chinese, Black, Filipino, Arab, Latin American, Southeast Asian, West Asian, Korean, Japanese, or other racial/ethnic minority) Indigenous populations (i.e., First Nations, Inuit, Métis, or other Indigenous group), Sexual/gender minorities (i.e., the LGBTQ2S+ community), Individuals living in rural and/or remote communities, Individuals living with a disability, Individuals with low social and economic conditions.
A dementia diagnosis impacts the cognitive, functional, and physical abilities of those diagnosed, which will influence their ability to perform activities of daily living including meal preparation and eating. Persons living with dementia can experience a range of difficulties while eating that will impact their ability to consume adequate food and fluids, which include but are not limited to swallowing, chewing, and self-feeding difficulties. Consequently, persons living with dementia are at increased risk of malnutrition and negative health outcomes. The objective of this study is to understand the experience of persons’ living with dementia or diagnosed memory problems and/or their caregivers in managing eating challenges and swallowing problems in the community.
You are eligible to participate if you:
- Speak English
- A person with memory problems experiencing eating challenges or swallowing problems in the community
- OR if you are or were a caregiver to a person with memory problems with eating challenges or swallowing problems.
The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment [MCI] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.
Age 50 - 85
Mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease
Must have a study partner
The purpose of this study is to assess the efficacy of an oral medication, IGC-AD1 that is a natural THC-based (Tetrahydrocannabinol) formulation, administered in micro doses, twice a day, on symptomatological Agitation, in patients with mild to severe dementia from Alzheimer's.
Diagnosis of Alzheimer's disease
Must have a study partner
Interested in learning how to better support people with dementia through the process of driving cessation? Take part in an online learning program about driving and dementia while participating in a research study. This program aims to equip HCPs with the knowledge and confidence to support people with dementia and their family/friend carers through the often challenging process of driving cessation. The objective of this study is to assess the impact of the e-learning program on HCPs’ knowledge, confidence and competence about driving cessation in the context of dementia. Information will be collected via questionnaires and interviews.
You are eligible to participate in this research if you are a healthcare provider such as a primary care physician, geriatrician, geriatric psychiatrist, nurse practitioner, occupational therapist or medical trainee/student who cares for people with dementia as part of your practice.